Lactobacillus casei PXN 37

What does the research say about Lactobacillus casei PXN 37?

2 health outcomes synthesised

Lactobacillus casei PXN 37 has been studied for 2 health outcomes: reduced inflammation and improved quality of life. The strongest evidence, based on 3 studies, supports a moderate effect on reducing inflammation in patients with autoimmune, neurodegenerative, and depression-related conditions. No consistent effective dose has been reported across studies, and the evidence base remains small and preliminary.

Strongest evidence: The most researched outcome for Lactobacillus casei PXN 37 is reduced inflammation, supported by 3 studies with low evidence strength. All 3 studies reported beneficial effects, with 2 showing moderate effect sizes and 1 showing a small effect. The evidence comes from meta-analyses in patients with autoimmune diseases, neurodegenerative conditions (Alzheimer’s, Parkinson’s, multiple sclerosis, mild cognitive impairment), and depressed patients with somatic comorbidities. No specific dose or study duration was consistently reported.

Mixed or weaker evidence: For improved quality of life, the evidence strength is very low, based on 3 studies that all reported beneficial effects but with mixed effect sizes (small to moderate). Many of these studies did not reach statistical significance, and the evidence derives from systematic reviews in colorectal cancer patients undergoing chemotherapy, neurodegenerative disease patients, and gastrointestinal disease patients. The small number of studies and lack of significant findings make this outcome uncertain.

Effective dose patterns: No effective dose, form, or duration data were reported in any of the included reviews for either outcome. Research syntheses did not provide sufficient information to identify a typical dosing range.

Population insights: Neurodegenerative disease populations (Alzheimer’s, Parkinson’s, multiple sclerosis, mild cognitive impairment) appear in both syntheses, suggesting a cross-cutting area of study. Autoimmune and depression populations are specific to the inflammation outcome, while cancer and GI patients are only represented in quality-of-life research.

Notable caveats: Both outcomes are based on only 3 studies each, making conclusions preliminary. The available evidence is overwhelmingly positive, but clinical literature in this area is subject to publication bias—null-result studies are less likely to be published. For quality of life, many studies did not reach statistical significance, indicating the actual effect may be smaller than the observed direction suggests.

Frequently asked

What is Lactobacillus casei PXN 37 good for according to research?
Research on Lactobacillus casei PXN 37 has focused on two outcomes: reducing inflammation and improving quality of life. All 3 studies for each outcome reported beneficial effects, but the evidence strength is low (inflammation) or very low (quality of life) due to small sample sizes and publication bias concerns.
Does Lactobacillus casei PXN 37 help reduce inflammation?
Three studies found that Lactobacillus casei PXN 37 reduced inflammation, with moderate effect sizes in 2 studies and a small effect in 1. The evidence is preliminary and comes from patients with autoimmune diseases, neurodegenerative conditions, and depression. No consistent dose or study duration was reported.
Does Lactobacillus casei PXN 37 improve quality of life?
Three studies reported beneficial effects on quality of life, with effect sizes ranging from small to moderate. However, the evidence strength is very low because many studies did not reach statistical significance, and the research was conducted in specific patient groups such as colorectal cancer patients undergoing chemotherapy and those with neurodegenerative or gastrointestinal diseases.
What dose of Lactobacillus casei PXN 37 is typically used in studies?
No specific dose, form, or duration of use was reported in the research syntheses for either outcome. The included reviews did not provide consistent dosing information, so no typical dose can be identified from the current evidence.
Who benefits most from Lactobacillus casei PXN 37 according to research?
Patients with neurodegenerative diseases (Alzheimer’s, Parkinson’s, multiple sclerosis, mild cognitive impairment) appear in studies for both inflammation and quality of life. Other populations studied include patients with autoimmune diseases, depression (for inflammation), and colorectal cancer or gastrointestinal conditions (for quality of life). All findings are preliminary.
Are there caveats or limitations in the research on Lactobacillus casei PXN 37?
Yes. The evidence base for both outcomes is very small (only 3 studies each), and conclusions are preliminary. The available research is overwhelmingly positive, but this may reflect publication bias—negative or null studies are less likely to be published. For quality of life specifically, many studies did not reach statistical significance, suggesting the true effect may be smaller.

Most-studied combinations with Lactobacillus casei PXN 37

most supplement research is combination research

Also studied with:Lactobacillus rhamnosus PXN 54 (6), Streptococcus thermophilus PXN 66 (8)